Creative Medical Tech Reports Minimal Revenue in Q2 2024

TL;DR

CMED barely making any money, assets at $10M.

AI Summary

Creative Medical Technology Holdings, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported minimal revenue, with $0.001 million in revenue for the six months ended June 30, 2024, compared to $0.001 million for the same period in 2023. Total assets were $10 million as of June 30, 2024.

Why It Matters

This filing indicates a company with very low revenue generation, which could signal significant challenges in commercializing its products or services.

Risk Assessment

Risk Level: high — The company's extremely low revenue and lack of significant financial activity suggest a high risk of financial instability and potential failure.

Key Numbers

• $10 million — Total Assets (As of June 30, 2024, indicating the company's overall financial size.)
• $0.001 million — Revenue (YTD) (For the six months ended June 30, 2024, highlighting minimal sales activity.)
• 10000000 — Total Assets (Numerical value for total assets as of June 30, 2024.)
• 40000 — Warrants (Number of warrants outstanding as of June 30, 2024.)
• 100000 — Options (Number of options outstanding as of June 30, 2024.)

Key Players & Entities

• CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (company) — Filer
• 0001187953 (company) — Central Index Key
• 20240630 (date) — Reporting Period End Date
• $10 million (dollar_amount) — Total Assets as of June 30, 2024
• $0.001 million (dollar_amount) — Revenue for six months ended June 30, 2024

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share CELZ The NASDAQ Stock Mar
• $0.01 — ny's shares of common stock trade below $0.01 per share for two or more consecutive t

Filing Documents

• celz_10q.htm (10-Q) — 669KB
• celz_ex311.htm (EX-31.1) — 13KB
• celz_ex312.htm (EX-31.2) — 12KB
• celz_ex321.htm (EX-32.1) — 5KB
• celz_ex322.htm (EX-32.2) — 6KB
• celz_10qimg1.jpg (GRAPHIC) — 28KB
• 0001477932-24-004635.txt ( ) — 3010KB
• celz-20240630.xsd (EX-101.SCH) — 29KB
• celz-20240630_lab.xml (EX-101.LAB) — 188KB
• celz-20240630_cal.xml (EX-101.CAL) — 29KB
• celz-20240630_pre.xml (EX-101.PRE) — 159KB
• celz-20240630_def.xml (EX-101.DEF) — 101KB
• celz_10q_htm.xml (XML) — 312KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements Unaudited Condensed Consolidated Balance Sheets 3 Unaudited Condensed Consolidated Statements of Operations 4 Unaudited Condensed Consolidated Statements of Cash Flows 5 Unaudited Condensed Consolidated Statements of Stockholder' Equity (Deficit) 6 Notes to Unaudited Condensed Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 15 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 19 Item 4.

Controls and Procedures

Controls and Procedures 19

– OTHER INFORMATION

PART II – OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 20 Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities 20 Item 6. Exhibits 21 2 Table of Contents CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS June 30, 2024 December 31, 2023 ASSETS CURRENT ASSETS Cash $ 7,471,476 $ 3,466,867 Investments - 6,520,191 Inventory 3,394 6,594 Prepaids and other current assets 129,086 277,246 Total Current Assets 7,603,956 10,270,898 OTHER ASSETS Other assets 3,281 3,281 Licenses, net of amortization 382,469 441,011 TOTAL ASSETS $ 7,989,706 $ 10,715,190 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES Accounts payable $ 322,158 $ 317,280 Accrued expenses 39,920 39,920 Advances from related party 14,194 14,194 Total Current Liabilities 376,272 371,394 TOTAL LIABILITIES 376,272 371,394 STOCKHOLDERS' EQUITY Preferred stock, $ 0.001 par value, 10,000,000 shares authorized at June 30, 2024 and December 31, 2023 - - Series B preferred stock, $ 0.001 par value, 1 share authorized, issued and outstanding at June 30, 2024 100 - Common stock, $ 0.001 par value, 5,000,000 and 50,000,000 shares authorized; 1,431,126 and 1,431,126 issued and 1,338,126 and 1,373,626 outstanding at June 30, 2024 and December 31, 2023, respectively 1,431 1,431 Additional paid-in capital 69,730,073 69,711,749 Accumulated deficit ( 61,697,704 ) ( 59,098,432 ) Treasury stock, at cost, 93,000 and 57,500 shares as of June 30, 2024 and December 31, 2023 ( 420,466 ) ( 270,952 ) 7,613,434 10,343,796 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 7,989,706 $ 10,715,190 The accompanying notes are an integral part of these condensed consolidated financial statements 3 Table of Contents CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended June 3

View Full Filing

View this 10-Q filing on SEC EDGAR